A trial compared once-daily oral safiglipron against dapagliflozin in adults with type 2 diabetes. Safiglipron lowered HbA1c at least as much as dapagliflozin at every dose tested, and by more at 90 mg. Weight loss was modest and similar in both arms.
Why it is interesting: An oral agent tested against a standard oral diabetes drug rather than against placebo.
Cite this item
BibTeX
Free sign-up. A digest of the new papers twice a week, grouped by domain.